Loading...
XKRX095700
Market cap162mUSD
Jan 07, Last price  
5,620.00KRW
1D
4.74%
1Q
-10.45%
Jan 2017
-86.70%
IPO
-67.29%
Name

Genexine Inc

Chart & Performance

D1W1MN
XKRX:095700 chart
P/E
—
P/S
52.62
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.42%
Rev. gr., 5y
-19.24%
Revenues
4.43b
-72.57%
6,251,652,91032,519,853,39211,351,915,01428,454,503,37112,881,557,48211,303,045,03018,543,494,61636,828,454,64516,139,032,1664,426,626,990
Net income
-66.87b
L+18.83%
-2,096,046,609-1,426,677,194-30,932,738,688-19,329,560,416-34,066,759,817-16,509,197,49227,569,725,330-47,726,585,050-56,274,592,376-66,873,517,570
CFO
-38.05b
L-4.38%
1,668,236,620-1,642,633,914-14,099,260,886-26,104,449,145-20,054,235,453-41,571,708,994-22,690,958,697-12,745,359,886-39,799,586,489-38,054,511,580
Dividend
Mar 15, 20220.285 KRW/sh
Earnings
Feb 05, 2025

Profile

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.
URL
http://genexine.com/
IPO date
Sep 15, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,426,627
-72.57%
16,139,032
-56.18%
Cost of revenue
37,701,581
38,224,388
Unusual Expense (Income)
NOPBT
(33,274,954)
(22,085,356)
NOPBT Margin
Operating Taxes
16,840,063
(857,243)
Tax Rate
NOPAT
(50,115,017)
(21,228,113)
Net income
(66,873,518)
18.83%
(56,274,592)
17.91%
Dividends
Dividend yield
Proceeds from repurchase of equity
84,222,990
1,975,958
BB yield
-21.02%
-0.32%
Debt
Debt current
44,693,156
65,432,655
Long-term debt
22,904,729
18,650,694
Deferred revenue
266,391
Other long-term liabilities
2,422,676
10,022,845
Net debt
(157,323,103)
(157,997,617)
Cash flow
Cash from operating activities
(38,054,512)
(39,799,586)
CAPEX
(7,378,740)
(31,779,107)
Cash from investing activities
(34,282,641)
(1,915,435)
Cash from financing activities
60,426,641
31,632,260
FCF
(54,295,307)
(37,132,343)
Balance
Cash
64,482,203
21,942,206
Long term investments
160,438,784
220,138,759
Excess cash
224,699,656
241,274,014
Stockholders' equity
(347,013,085)
(274,609,417)
Invested Capital
713,766,557
649,722,818
ROIC
ROCE
EV
Common stock shares outstanding
40,477
42,432
Price
9,900.00
-31.18%
14,384.62
-67.92%
Market cap
400,721,815
-34.35%
610,368,885
-60.77%
EV
243,680,519
457,124,932
EBITDA
(28,243,567)
(17,213,477)
EV/EBITDA
Interest
4,110,901
3,327,810
Interest/NOPBT